杰拉尼尔-杰拉尼拉作为术后心房的预防 (天才)
Kennedy S Ramos1, Soufiane Nassiri2, Leonoor F J Wijdeveld3
1Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Amsterdam University Medical Center, Location Vrije Universiteit Amsterdam, De Boelelaan 1117, Physiology, 1081 HV Amsterdam, The Netherlands. k.silvaramos@amsterdamumc.nl.
Cardiovascular drugs and therapy
|April 14, 2025
概括
这项研究调查了Geranylgeranylacetone (GGA) 是否可以在心脏手术患者中预防术后心房动 (PoAF). 预计结果将显示GGA的GGA.
科学领域:
- 心脏病学和心脏外科手术
- 药理学和治疗学 药理学和治疗学
- 生物医学研究生物医学研究
背景情况:
- 手术后心房动 (PoAF) 影响心胸外科手术后30-50%的患者.
- 目前对PoAF的预防疗法仍然不理想.
- 之前的研究表明,Geranylgeranylacetone (GGA) 增强了心脏保护性热冲击蛋白 (HSP).
研究的目的:
- 为了评估口服Geranylgeranylacetone (GGA) 预防PoAF的疗效.
- 评估GGA在接受选择性心胸外科手术的患者中降低AF发生率的潜力.
主要方法:
- 一个第二阶段,单中心,双盲,安慰剂对照随机试验 (GENIALITY研究).
- 接受选择性开放心脏手术的146名成年患者每天接受300毫克GGA或安慰剂.
- 治疗开始于手术前5天到手术后3天,在霍尔特监测下直到出院.
主要成果:
- 主要终点:GGA和安慰剂组之间的PoAF发病率的比较.
- 二级终点:通过生物化学分析评估热冲击蛋白 (HSP) 水平.
- 分析血液中的蛋白质稳定标记物,心房附属物和心表脂肪组织.
结论:
- 这项研究旨在证明,通过GGA治疗,PoAF发生率有所降低.
- 预计将为GGA在防止PoAF的有益作用提供概念证明.
- 它有可能将GGA作为心胸外科手术患者的新疗法策略.
相关概念视频
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
654
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
654
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
396
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
396
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
704
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
704
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.1K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
832
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
832
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
321
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321